UBS analyst Thomas Wadewitz lowered the firm’s price target on RXO Inc. (RXO) to $14 from $24 and keeps a Neutral rating on the shares. Muted industry demand hampered RXO’s results, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO, Inc. Hold Rating: Balancing Progress with Market Challenges and Freight Recession Concerns
- RXO, Inc. Reports Strong Revenue Growth Amid Integration Success
- Cautious Outlook on RXO, Inc. Amid Market Volatility and Financial Challenges
- RXO, Inc. Hold Rating: Navigating Market Challenges and Coyote Integration Amid Mixed Q1 Results
- RXO Inc. price target lowered to $23 from $25 at Morgan Stanley